Product Development
Development
Commercialization
- Support and brokerage in product portfolio optimization
Clinical Trials
Study set-up
- Paediatric Investigation Plan
Study conduct

CSR writing / preparation

Full service Clinical Research Organization

PhV in Clinical Trials
Quality
CMC development
Technology and analytical methods
- Analytical Methods Transfer
GMP system
- GMP system implementation
- Product certification
GxP Audits
GMP
GCP
- GCP Audits (remote and on site)
PhV
- GVP Audits (remote and on site)
GLP
- GLP Audits (remote and on site)
Regulatory Affairs
Pre-authorisation
- Scientific Advice
- Product information
  
  Preparation of product information
  
  Package Leaflet readability test
  
  Bridging Report
  
  Translation of Patient Information
  
  Product Information and mock-ups verification
- Dossier preparation
  
  Medical writing - preparation of registration dossier
  
  CTD Module 3 - Quality
  
  Product information
  
  Enviromental Risk Assessment (ERA)
  
  Orphan Medicinal products
- Dossier Gap Analysis
MA Handling
- Handling of the registration process
- eCTD compilation
Post-authorisation
Regulatory outsourcing
- Regulatory consulting in the pharmaceutical industry
Pharmacovigilance
PhV system
- Pharmacovigilance system (PSMF)
- RMP Development and maintenance
PhV post-authorisation
Clinical trials

EU QPPV service
QP Service / Importer

QP Service

Import and supply chain management

MIA Certificate

GMP Certificate

RFI

MENU

pl
en

SciencePharma/

News & Insights

/ Blog /

EMA: New guide on bi...

EMA: New guide on biosimilar medicines for healthcare professionals

The European Medicines Agency (EMA) and the European Commission have published an information guide for healthcare professionals on biosimilar medicines. Biosimilars are biological medicines that are highly similar in all essential aspects to a biological medicine that has already been authorised.

RETURN